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Abbreviations and definitions of terms 
 
ADRS Aphasia Depression Rating Score 
AE Adverse Event 
ACTRN Australasian Clinical Trial Registry Number 
AQ Aphasia Quotient (derived from Western Aphasia Battery)  
AusTOMS Australian Therapy Outcome Measures 
BNT Boston Naming Test 
CIUs Correct Information Units 
CONSORT Consolidated Standards of Reporting Trials 
CRF Case Report Form 
CTA Clinical Trial Agreement 
DSMC Data Safety Monitoring Committee 
eCRF Electronic Case Report Form 
ECU Edith Cowan University 
FAST Frenchay Aphasia Screening Test 
FDA Food and Drug Administration 
GCP Good Clinical Practice 
GEE Generalised Estimating Equations 
GLMM Generalised Linear Mixed Model 
GP General Practitioner 
IEC Independent Ethics Committee 
IME Important Medical Event  
IQR Interquartile Range 
LMM Linear Mixed Model 
mRS Modified Rankin Score 
MAR 
NHMRC 
Missing at Random 
National Health and Medical Research Council 
NIHSS National Institute of Health Stroke Score 
NTA Neuroscience Trials Australia 
OCSP Oxfordshire Community Stroke Project Classification 
RBHOM Royal Brisbane Hospital Outcome Measure for Swallowing  
RCT Randomised Controlled Trial 
SAE Serious Adverse Event 
SAQoL-39 Stroke and Aphasia Quality of Life 
SAH Sub Arachnoid Haemorrhage 
SD Standard Deviation 
SDH Sub Dural Haemorrhage 
TIA Transient Ischemic Attack 
TGA Therapeutic Goods Administration 
UC Usual Care 
UTN Unique Trial Number  
VERSE Very Early Rehabilitation in SpEech 
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WAB- R Western Aphasia Battery-Revised  
%MPR Percent of Maximal Potential Recovery 
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1 Study Design 
1.1 Overview 
VERSE1 is a prospective, parallel group, assessor blinded, randomised, multicentre, international 
clinical trial. Ethics and local governance approval was obtained from all sites participating. Version 
3 of the protocol is current at the time of publication. Written, informed consent is obtained from each 
participant or their legal representative using full hospital approved consent processes supported by 
aphasia friendly consent documents. All participants in VERSE receive usual ward based care. 
Participants are randomised in a ratio of 1:1:1 to one of three groups (i) usual ward care alone (UC); 
or (ii) usual ward care plus high intensity aphasia therapy (UC-Plus); or (iii) usual ward care plus 
high intensity prescribed and structured aphasia therapy (VERSE). The distinguishing features of 
each of these arms is described in Section 1.5. 
 
1.2 Aims and hypotheses 
The primary aim of the VERSE trial is to determine whether very early daily aphasia therapy (UC-
Plus and VERSE groups) is superior to usual ward care at 12 weeks post stroke. The secondary aim 
is to test whether a standardised intense aphasia therapy regimen (VERSE) is more effective and cost 
effective than non-standardised intense aphasia therapy (UC-Plus). Participants are recruited within 
the first 14 days following stroke. For the purposes of this trial, aphasia therapy refers to direct aphasia 
treatment designed to change the communication performance of the person with aphasia. All 
analyses herewith include only direct aphasia therapy which does not include patient/family 
counselling and education, case management or documentation. 
Primary Hypothesis: 
Very early aphasia therapy will result in greater improvement in communication at 12 weeks post-
stroke, as measured by the Western Aphasia Battery-Revised; Aphasia Quotient (WAB-R (AQ)).2 
Secondary Hypotheses: 
1. VERSE aphasia therapy will result in a greater improvement in communication than UC-Plus 
aphasia therapy at 12 and 26 weeks post stroke, as measured by the WAB-R (AQ).2 
2. VERSE aphasia therapy and UC-Plus will each result in greater improvements in 
communication than UC alone, as measured by the WAB-R(AQ)2, at 12 weeks and 26 weeks 
post stroke. 
3. VERSE aphasia therapy will result in greater improvements in connected speech than UC-
Plus, as measured by Discourse Analysis, at 12 weeks and 26 weeks post stroke. 
4. VERSE aphasia therapy and UC-Plus will each result in greater improvements in connected 
speech than UC alone, as measured by Discourse Analysis, at 12 weeks and 26 weeks post 
stroke. 
5. Very early aphasia therapy (UC-Plus and VERSE) will result in better quality of life at 12 and 
26 weeks post stroke than UC control.  
6. Very early aphasia therapy (UC-Plus and VERSE) will be more cost-effective than UC at 12 
and 26 weeks post stroke.  
 
1.3 Patient Population 
Participants include patients with acute stroke and aphasia screened using the shortened Frenchay 
Aphasia Screening Test.3 Participants are identified, recruited, randomised and assessed within 14 
days of stroke. Therapy commences the day after this assessment.  
 
 Page 7 of 29 
VERSION 1.1    
DATE:  28 March 2018 
   
 
 
1.3.1 Inclusion Criteria 
Patients are eligible if the following inclusion criteria are met: 
• The patient has acute aphasia of any type resulting from an acute stroke (ICD 10 codes 161 – 
164 i.e. no TIA, SAH or SDH);  
• The patient has a score of less than 93.7 of the Aphasia Quotient of the Western Aphasia 
Battery-Revised2 
• The patient is deemed medically stable at recruitment  
• The patient can maintain a wakeful alert state for 30 consecutive minutes within 14 days of 
stroke onset  
• The patient has normal or corrected hearing and vision  
• The patient is at least 18 years old; there is no upper age limit for inclusion. 
• Informed consent is obtained from the patient or person responsible 
 
1.3.2 Exclusion criteria  
Patients are excluded from the study if they have any of the following: 
• Pre-existing aphasia before the stroke event 
• Have suffered a head injury or have had or require neurosurgery (clot retrieval surgery is not 
an exclusion if patient is stable post operatively and meets the above criteria)  
• Pre-existing clinical diagnosis of dementia  
• Diagnosis or treatment of major depression at the time of enrolment 
• Concurrent progressive neurological disorders 
• Unable to participate in English based therapy due to English being a second language.   
• Is participating in another intervention trial, which in the opinion of the VERSE trial manager, 
may interfere with the outcome of the VERSE trial.  
 
1.4 Randomisation 
Participants are randomised to one of three groups (UC, UC-Plus, VERSE) via a central allocation 
system in a 1:1:1 ratio. Randomisation is stratified by aphasia severity on the WAB-AQ2 (Severe: 
WAB-AQ2 0-31.2; Moderate: WAB-AQ2 31.3-62.5; Mild: WAB-AQ2 62.6-93.7). A remote, web-
based, computer-generated randomisation procedure is used. All online data submissions are secured 
by use of password site entry and data encryption procedures. Once the site staff submits patient 
recruitment data, the randomisation allocation is immediately provided back to the investigator. 
 
1.5 Intervention 
Participants randomised to one of three arms of therapy receive direct aphasia therapy with a qualified 
speech pathologist for a maximum period of 25 working days. The three arms are: 
1 Usual Care: Usual ward based aphasia care provided as per health care site standards. 
2 UC-Plus: Usual ward based care for aphasia is provided but using a defined therapy regimen of 
daily sessions of 45 – 60 minutes; each participant receives 20 sessions (15 – 20 hours of direct 
aphasia therapy) in addition to usual care.   
3 VERSE intervention: The intensity of this arm of therapy will match the Usual Care-Plus arm, 
(20 daily sessions of 45 – 60 minutes duration; 15 – 20 hours of direct aphasia therapy) but the speech 
and language training is prescribed and standardised according to a separate VERSE intervention 
protocol, in addition to usual care. 
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The intervention period for the trial concludes at a maximum of 50 days post stroke or when 20 
sessions of aphasia therapy are completed (UC–Plus and VERSE) – whichever comes first. 
Participants are followed up at 12 weeks and 26 weeks post stroke. 
Details of the intervention are provided in the VERSE Trial protocol (IJS, 2016). 
 
 
1.6 Baseline and follow-up assessments 
All stroke patients with aphasia, who are at least 18 years old, are screened for inclusion in the study. 
Those screened and deemed ineligible for the study are entered onto a screening log which outlines 
the reason for non-inclusion. Details of the screening and recruitment procedures, as well as the 
assessment schedule are included in the main trial protocol.  
The assessment timeline is outlined in Figure 1. Baseline assessment occurs no earlier than two days 
from the onset of stroke and no later than 14 days from the onset of stroke. Participants undergo the 
(AQ) component of the WAB-R.2 Participants are also assessed for their medical and stroke history. 
Baseline data collection includes the collection and documentation of:  
1) Demographic details including age, gender, past medical history, languages spoken, 
education level, handedness, employment, Aboriginal or Torres Strait islander status and 
living arrangements.  
2) Stroke type and severity (type, hemisphere, first or recurrent stroke, National Institute of 
Health Stroke Scale, (NIHSS4), modified Rankin Scale (mRS5), Oxfordshire Community 
Stroke Project Classification (OCSP6), Royal Brisbane Hospital Outcome Measure for 
Swallowing (RBHOM7) and Australian Therapy outcome measures (AusTOMS8). 
3) Additional baseline assessments including the Boston Naming Test (BNT9), the “clock 
drawing” cognitive sub test, and discourse collection. 
4) Time of assessment and aphasia therapy commencement.  
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Therapy commences the day after the baseline assessment, and is completed within a maximum of 
25 working days and must be completed by day 50 post stroke.  
The participants are followed up at their place of residence or in the hospital clinic by a blinded 
assessor, 12 weeks and 26 weeks after the date of the stroke. Patient assessments at these follow-up 
visits include: 
• the Aphasia Quotient component of the Western Aphasia Battery-Revised2 
• the Boston Naming Test,9  
• Discourse collection,10-16 
• Stroke and Aphasia Quality of life questionnaire 39 item version17; and  
• The Aphasia Depression Rating Scale.18 
 
1.7 Sample Size Considerations 
The study is powered to detect a difference of 4.4% in communication improvement, measured as 
percent of maximal improvement (%MPR) on the WAB-AQ.2 This is based on the smallest difference 
between VERSE and UC-plus estimated from our pilot studies. We have consulted international 
aphasia experts who have reported a previous consensus that a 5-point difference on the WAB-AQ2 
is clinically meaningful improvement in communication. It is important to note this relationship is 
not linear and will vary based on aphasia severity. We believe the 4.4% change in communication 
status, which is marginally more conservative than the 5-point difference reported in consensus is 
reasonable, given this is the difference between the two intensive arms of this trial. The required 
sample size was estimated under the assumption that the effectiveness hypotheses would be analysed 
using a longitudinal regression model (generalised estimating equations or linear mixed model), with 
outcomes measured at three times (at baseline, 12 and 26 weeks months).   
A sample of 246 participants (82 per arm) will provide 80% power to detect this difference at a (two-
sided) significance level of α = 0.05, after adjusting for a 20% loss to analysis of (lost to follow-up 
due to death, dropout and non-adherence). 
Our pilot data shows similar effect sizes for differences between the VERSE and UC-plus 
interventions for discourse measures and communication outcomes. Therefore, we believe that the 
sample size will provide sufficient power to assess differences in discourse outcomes. Pilot data on 
quality of life for this population was not available at the trial inception however, we expect to observe 
larger effects on quality of life than on communication or discourse and therefore expect to have 
sufficient power to assess difference on quality of life. 
 
1.8 Other Data Collection 
During the intervention period, all Usual Care speech therapy is documented in medical notes. The 
detail of all additional trial related aphasia therapy is documented separately on the electronic Case 
Report Form (eCRF) as part of the clinical trial. A daily speech therapy log is completed for each 
trial participant which includes content, duration of session and frequency of sessions. Where usual 
care sessions with participants have occurred prior to the participant’s enrolment in the trial, these 
sessions are retrospectively collected from the participant’s medical record to ensure all therapy 
provided to the participant enrolment is captured. Deviation from the prescribed therapy intensity 
protocol (UC–Plus and VERSE), is documented. Reasons for withdrawal of therapy such as health 
related complications, patient withdrawal and death are recorded. At the end of the treatment period, 
a participant diary is provided to the patient to capture resource utilisation information.  
Participants are assessed and questioned about general health to determine if there have been any 
adverse or Serious Adverse Events during the study period. 
The assessment visits (Baseline, Week 12 and Week 26) are completed as a single session. If the 
participant is unable to complete assessment tasks in a single session, they are completed on the same 
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day if possible (ie: over a morning and afternoon session). If this is not possible, the assessments take 
place on consecutive days and a protocol deviation is recorded. 
Information relating to resource utilisation is obtained by the blinded assessor from the participant 
and the participant diary and includes general practitioner (GP) visits, hospital and rehabilitation 
admissions, outpatient and community service use, medication use for anxiety and depression, speech 
therapy, use of speech aids and devices, employment status, respite care and informal care as a result 
of stroke. Where possible, resource utilisation data is verified in medical or other hospital records. 
 
1.9 Blinding 
VERSE is a complex intervention and therefore, it is difficult to blind the participants to receipt of 
intense treatment or usual care. Similarly, it is not possible to blind the clinician providing therapy to 
the participant’s treatment allocation. Every effort is made to ensure only minimal staff are aware of 
randomisation allocation, and all outcome assessments are conducted by assessors who are blinded 
to allocation. In addition, chief investigators and trial statistician are blinded to treatment allocation. 
 
1.9.1 Unblinding 
Only the Data and Safety Monitoring Committee (DSMC) have access to progressive data. The 
DSMC Chair is Professor Richard Lindley, University of Sydney, NSW, Australia. The DSMC 
review unblinded data in accordance with the DSMC Charter (Version 1.0, 25 February 2015). 
 
1.10 Definition of the Outcomes 
1.10.1 Primary Outcome 
The primary outcome is improvement in communication at 12 weeks after stroke. Communication 
outcome is measured by the Western Aphasia Battery- Revised Aphasia Quotient (WAB-R (AQ)).2 
Improvement will be assessed using the percent of maximal potential recovery achieved (%MPR).19 
A formal definition of %MPR19 is provided in Section 3.5.1. 
 
1.10.2 Secondary Outcome Measures 
The secondary outcome measures include effectiveness, quality of life, safety and cost effectiveness 
measures. These are: 
• Communication improvement at 26 weeks, assessed as %MPR19 at 26 weeks 
• Improvement in connected speech at 12 and 26 weeks on discourse measures10-16 
• Quality of life measured by the Stroke and Aphasia Quality of Life (SAQOL)17 scale 
• Depression measured at 12 and 26 weeks by the Aphasia Depression Rating Scale (ADRS)18 
• Adverse Events and serious adverse events as defined in the trial protocol 
• Cost effectiveness of VERSE and UC-Plus therapies compared to Usual Ward Care. The 
economic analysis will be outlined separately in an Economic Analysis Plan 
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2 Funding 
 This study is funded by the National Health and Medical Research Council (NHMRC), Australia 
(Project Grant Number 1044973), The Tavistock Trust for Aphasia, United Kingdom and Edith 
Cowan University, Australia. The funders of this study have no influence on the study design, data 
collection, data interpretation,  writing of the protocol or statistical analysis plan. 
 
3 Statistical Plan 
  
3.1 Analysis principles and general considerations 
• All outcomes and analyses are prospectively characterised as primary or secondary. 
• Differences in all endpoints between the three arms of the trial (VERSE, UC-Plus, UC) will 
be tested independently at the two-tailed 5% significance level. All estimates of treatment 
effects will be presented with 95% confidence intervals. 
• No formal adjustments will be undertaken to constrain the Type I error associated with 
planned secondary or exploratory analyses. The information provided by analyses is designed 
to supplement the evidence from the primary analyses; it will provide a more complete 
characterization of the treatment effects. 
• The analyses for all outcome measures (effectiveness, quality of life and safety) will be 
conducted on an intention the treat (ITT) basis i.e. all patients will be analysed as members of 
the group to which they were randomised, irrespective of whether they received the allocated 
treatment or not. The ITT strategy for VERSE is based on the following principles: 
o All available outcome data are collected on all randomised patients. 
o All participants are analysed in the groups to which they are randomised. 
o All available outcome data will be used in the primary analyses. The primary analyses 
will be reported without missing data imputed. 
o A separate analysis with missing data imputed will also be reported. Missing data will 
be assumed to be missing at random (see section 3.5.3) 
o A sensitivity analysis including all randomised individuals will be conducted. The 
sensitivity analysis will consider alternative assumptions about data missing not at 
random (MNAR) (see section 3.10). 
• A per-protocol analysis will be conducted separately, but will not be included in the primary 
results for this trial. The per-protocol analysis will be described in greater detail when it is 
published. However, it will be based on the following principles: 
o The per-protocol cohorts will be based on whether or not participants received the 
planned minimum 15 hours of direct aphasia therapy as the intervention dose. 
o The per-protocol cohort will include:  
 VERSE participants who receive at least 15 hours of direct language therapy 
over the intervention period;  
 UC-Plus participants who receive at least 15 hours of direct language therapy 
over the intervention period;  
 All UC participants who are randomised to the UC group.  
• For primary and secondary analyses, the treatment effects for the primary effectiveness 
outcomes will be adjusted for baseline aphasia severity, measured by the WAB-R (AQ)2 and 
baseline stroke severity measured with the NIHSS.4 Unadjusted analyses will be reported 
separately from these pre-specified analyses. 
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• Subgroup analyses will be carried out irrespective of whether there is a significant treatment 
effect on the primary outcome. Their purpose is to supplement evidence from the primary 
analyses to help to fully characterize the treatment effect. Results from subgroup analyses will 
be interpreted in this context. 
• Analyses will primarily be conducted using the R Statistical Programming Language20 and 
supplemented with SPSS21 to generate formatted tables. 
 
3.2  Interim Analysis and Stopping Rules 
There are no formal interim analyses planned for this trial. The DSMC periodically reviews data for 
the primary outcome measure and safety, and will advise the chair of the Executive committee if, in 
their view, the randomised comparisons have provided both (i) ‘proof beyond reasonable doubt’ that 
very early aphasia rehabilitation (VERSE and UC-Plus groups) is clearly indicated or clearly contra-
indicated because of safety concerns and (ii) evidence that might influence future patient 
management. The DSMC are guided by Haybittle-Peto boundaries in making this determination. That 
is, they work on the principle that a difference of at least 3 standard errors in the analysis of 
effectiveness or serious adverse events (e.g. death from all causes, aspiration pneumonia within the 
first 50 days post stroke) may be needed to justify halting, or modifying the study before the planned 
recruitment is completed.  
 
3.3 Trial Profile 
The trial will be reported in accordance with the CONSORT statement for non-pharmaceutical trials19 
and the VERSE therapeutic protocol conforms to the SPIRIT statement.22,23 The report will include 
the number of screened patients who met the inclusion criteria, the number included, and the major 
reasons for exclusion of eligible patients. At follow up, the number of patients withdrawn, lost to 
follow up and the number who died within that period will be reported. 
 
3.4 Patient Characteristic and baseline comparisons 
Baseline participant and stroke characteristics will be presented for each of the three groups: UC, 
UC-Plus and VERSE (Table 1). These will include: age, gender, geographic region (Australia/NZ), 
stroke risk factors, stroke type, stroke severity (NIHSS),4 mRS,5 time to randomisation and baseline 
assessment. Baseline communication, cognition and swallowing characteristics will be presented in 
Table 2 and will include Aphasia severity, as measured by the WAB-R (AQ),2 clock drawing test, 
Discourse Scores (words, correct information units),11-16 AuSTOMS,8 and RHBOMS.7 
Discrete variables will be summarized as frequencies and percentages. Unless otherwise indicated 
in the tables, percentages will be calculated according to the number of patients for whom data are 
available. If there are more than 5% missing values, the denominator will be indicated in the 
corresponding summary table. Continuous variables will be summarized by the mean and standard 
deviation (SD) or by the median and interquartile range (IQR). Durations and time intervals will be 
summarized by medians and IQRs.  
3.5 Primary Outcome: Communication Recovery at 12 weeks by Intensity 
3.5.1 Primary Outcome Measure 
The primary outcome is improvement in communication at 12 weeks after stroke. Communication 
outcome will be measured by the WAB-R (AQ).2 The WAB-R (AQ) is a comprehensive measure 
incorporating production of spoken language and auditory comprehension. Improvement will be 
assessed using the percent of maximal potential recovery achieved (%MPR),19 which is calculated as 
the ratio of the difference in WAB-R (AQ)2 at 12 weeks and WAB-R (AQ)2 at baseline, divided by 
the difference of maximal attainable score on WAB-R (AQ)2 and the WAB-R (AQ)2 at baseline. That 
is, 
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3.5.2 Statistical Hypothesis 
The primary research hypothesis is that:  
Compared to usual care alone, providing very early daily aphasia therapy (UC-Plus or VERSE) will 
result in greater improvements in communication ability at 12 weeks post stroke. This will be tested 
by refuting the null hypothesis that there is no difference in communication recovery, between the 
usual care group (UC) and the groups receiving very early intensive therapy (UC-Plus or VERSE) at 
12 weeks post stroke. For purpose of testing this intensity hypothesis, the UC-Plus and VERSE 
groups will be combined into a single high intensity group. 
3.5.3 Treatment of Missing Values 
The primary analyses will be presented both with and without imputation of missing data. The 
imputation will treat missing values as missing at random (MAR). i.e. it will be assumed that the 
missing data are related to observed data, but not related to the value of the missing data itself. That 
is, it is assumed that the values of the missing data may reasonably be predicted from all observed 
data. In particular, it will be assumed that missing values of the primary outcome measure (WAB-R 
(AQ)2 at 3 months) may be estimated from variables on which data has been collected (e.g. baseline 
aphasia severity, baseline stroke severity, age, gender, lesion size and location), and on the observed 
values of WAB-R (AQ).2 Multiple imputations will be conducted using chained equations.22 A 
separate model will be developed for each imputation. The pooled result of these imputed models 
will be reported and compared with the primary model (without imputed data). 
Based on monitoring by the DSMC, 13% of the data for the primary outcome measure in the VERSE 
trial is missing at the time of publication of the statistical analysis plan. This is substantially less than 
in previous aphasia trials and less than the 20% missing data that had been planned for in the planning 
of this trial.1 The assumption that the data are missing at random was discussed by the VERSE 
Executive Committee as well as the DSMC, and considered to be plausible based on the information 
available at the time. Sensitivity analyses that consider various other plausible assumptions about 
missing data will be presented (see below section 3.10, page16). 
3.5.4 Analysis Method: 
The primary aim of this trial is to test the effect of intensity of therapy in early stroke recovery. This 
is achieved through the primary effectiveness hypothesis which will be analysed using a linear mixed 
effects regression model with %MPR16 as the outcome measure. The UC-Plus and VERSE groups 
will be combined into a single high intensity group. This combined intervention group will be 
compared to the UC group on the primary outcome measure (%MPR16 at 12 weeks). The model will 
adjust for differences in baseline aphasia severity and baseline stroke severity by including the 
baseline WAB-R(AQ)2 score and the baseline NIHSS4 score as covariates in the model. The effect of 
hospital site will be controlled for by including hospital site as a random effect. The treatment effect 
will be reported as difference in %MPR with the corresponding 95% confidence interval. 
Since publication of the trial protocol1 five new sites have been added to address low participant 
recruitment. As a result, the Executive Committee decided there was a need to include hospital site 
as a random effect. This required the adaptation of our original statistical plan from using General 
Estimating Equations model (GEE) to a Linear Mixed Effect Regression models. 
3.5.5 Subgroup Analyses: 
The linear mixed effects regression model will be modified to analyse the difference in the primary 
effectiveness outcome (%MPR16 at 12 weeks) between  
100X
)baselineat  (100
)baselineat  () weeks12at  ( =                                 
100X
)baselineat  ()score  attainable Maximum(
)baselineat  () weeks12at  ( =  weeks12at  %
AQ
AQAQ
AQAQ
AQAQMPR
−
−
−
−
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1) the VERSE group and UC group AND 
2) the UC- Plus group and the UC group 
As with the primary analysis, the model will adjust for differences in baseline aphasia severity and 
baseline stroke by including the baseline WAB-R(AQ)2 score and the baseline NIHSS4 score as 
covariates in the model. The effect of hospital site will be controlled for by including recruiting site 
as a random effect. The main between-group difference at each time point will be assessed through 
the interaction effect of group and timepoint. The treatment effect for each subgroup analysis will be 
reported as difference in %MPR16 with the corresponding 95% confidence interval. 
No corrections for multiple testing in subgroup analyses will be undertaken for these planned 
analyses. The unadjusted p-values will be reported together with the number of subgroup analyses 
undertaken. 
 
3.6 Secondary Effectiveness Hypotheses: 
The following secondary effectiveness hypotheses will be assessed:  
1. VERSE (standardised, daily very early) aphasia therapy will result in greater improvements 
in communication ability than UC-Plus (non-standardised daily very early), as measured by 
the WAB-R (AQ),2 at 12 weeks and 26 weeks post stroke. 
2. VERSE (standardised, daily very early) aphasia therapy and UC-Plus (non-standardised daily 
very early) will each result in greater improvements in communication ability than Usual Care 
alone (UC), as measured by the WAB-R (AQ),2 at 12 weeks and 26 weeks post stroke. 
3. VERSE (standardised, daily very early) aphasia therapy will result in greater improvements 
in connected speech than UC-Plus (non-standardised daily very early) as measured on 
Discourse Analysis10,11 (number of words, number of Content information units; % Content 
information units), at 12 weeks and 26 weeks post stroke. 
4. VERSE (standardised, daily very early) aphasia therapy and UC-Plus (non-standardised daily 
very early) will each result in greater improvements in connected speech than Usual Care 
alone (UC), as measured by Discourse Analysis10-16 (number of words, number of Content 
information units; % Content information units), at 12 weeks and 26 weeks post stroke. 
 
3.6.1 Secondary Statistical Hypotheses 
The specified set of secondary effectiveness hypotheses involve the assessment of the following 
statistical hypotheses: 
1. VERSE (standardised, daily very early) aphasia therapy will result in greater improvements 
in communication ability than UC-Plus (non-standardised daily very early), as measured by 
the WAB-R (AQ),2 at 12 weeks post stroke. 
2. VERSE (standardised, daily very early) aphasia therapy will result in greater improvements 
in ability than UC-Plus (non-standardised daily very early), as measured by the WAB-R 
(AQ),2 26 weeks post stroke. 
3. VERSE (standardised, daily very early) aphasia therapy will result in greater improvements 
in communication ability than Usual Care alone (UC), as measured by the WAB-R (AQ),2 12 
weeks post stroke. 
4. VERSE (standardised, daily very early) aphasia therapy will result in greater improvements 
in communication ability than Usual Care alone (UC), as measured by the WAB-R (AQ),2 26 
weeks post stroke. 
5. UC-Plus (non-standardised daily very early) will result in greater improvements in 
communication ability than Usual Care alone (UC), as measured by the WAB-R (AQ),2 12 
weeks post stroke. 
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6. UC-Plus (non-standardised daily very early) will result in greater improvements in 
communication ability than Usual Care alone (UC), as measured by the WAB-R (AQ),2 26 
weeks post stroke. 
7. VERSE (standardised, daily very early) aphasia therapy will result in greater improvements 
in connected speech than UC-Plus (non-standardised daily very early), as measured by 
Discourse Analysis,10-16 12 weeks post stroke. 
8. VERSE (standardised, daily very early) aphasia therapy will result in greater improvements 
in connected speech than UC-Plus (non-standardised daily very early), as measured by 
Discourse Analysis,10-16 26 weeks post stroke. 
9. VERSE (standardised, daily very early) aphasia therapy will result in greater improvements 
in connected speech than Usual Care alone (UC), as measured by Discourse Analysis,10-16 
12 weeks post stroke. 
10. VERSE (standardised, daily very early) aphasia therapy will result in greater improvements 
in connected speech than Usual Care alone (UC), as measured by Discourse Analysis,10-16 
26 weeks post stroke. 
11. UC-Plus (non-standardised daily very early), will result in greater improvements in connected 
speech than Usual Care alone (UC), as measured by Discourse Analysis,10-16 12 weeks post 
stroke. 
12. UC-Plus (non-standardised daily very early), will result in greater improvements in connected 
speech than Usual Care alone (UC), as measured by Discourse Analysis,10-16 26 weeks post 
stroke. 
 
3.6.2 Analysis Methods: 
 The outcome measure for all effectiveness analyses that involve WAB-R (AQ)2 will be %MPR.16 For 
outcomes assessed at 12 weeks post stroke, this will be %MPR16 at 12 weeks post stroke, as defined 
in section 3.5.1 above. For outcomes assessed at 26 weeks post stroke this will be %MPR16 at 26 
weeks as measured at baseline. That is, 
 
 
 
The outcome measure for all efficacy analyses involving Discourse Analysis10,11 will be %CIUs. 
 
3.6.2.1 Comparison between VERSE and UC-Plus groups: 
3.6.2.1.1 Communication Outcomes (WAB-R (AQ)2: 
A longitudinal linear mixed model will be used to assess difference between the VERSE and UC- 
Plus groups on %MPR16 at 12 weeks and 26 weeks. The main between-group difference at each time 
point will be assessed through the interaction effect of group and timepoint.  The model will adjust 
for baseline aphasia severity by including the WAB-R (AQ)2 score at baseline as a covariate. Baseline 
stroke severity will be controlled for by including the NIHSS4 at baseline as a fixed factor in the 
model. Recruitment site will be included as a random effect. 
3.6.2.1.2 Connected Speech Outcomes (Discourse Analysis): 
A similar longitudinal linear mixed model will be used to assess difference between the VERSE and 
UC-Plus groups on %CIUs10-16 at 12 weeks and 26 weeks. The main between-group difference at 
each time point will be assessed through the interaction effect of group and timepoint.  The model 
will adjust for baseline aphasia severity by including the WAB-R (AQ)2 score at baseline as a 
covariate. Baseline stroke severity will be controlled for by including the NIHSS4 at baseline as a 
fixed factor in the model. Recruitment site will be included as a random effect. 
100X
)baselineat  (100
)baselineat  () weeks26at  ( =   weeks26at  %
AQ
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−
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3.6.2.2 Comparison with UC group at 12 weeks and 26 weeks: 
 
3.6.2.2.1 Communication Outcomes (WAB-R (AQ2)): 
A longitudinal linear mixed model will be used to compare each of the VERSE and UC-Plus groups 
to the UC group on %MPR19 at 12 weeks and 26 weeks. The main between-group difference will be 
assessed through the interaction effect of group and time point.  The model will adjust for baseline 
aphasia severity by including the WAB-R (AQ)2 score at baseline as a covariate. Baseline stroke 
severity will be controlled for by including the NIHSS4 at baseline as a fixed factor in the model. 
Recruitment site will be included as a random effect. 
3.6.2.2.2 Connected Speech Outcomes (Discourse Analysis): 
A similar longitudinal linear mixed model will be used to compare each of the VERSE and UC- Plus 
groups to the UC group on %CIUs10-16 at 12 weeks and 26 weeks. The main between-group difference 
at each time point will be assessed through the interaction effect of group and timepoint.  The model 
will adjust for baseline aphasia severity by including the WAB-R (AQ)2 score at baseline as a 
covariate. Baseline stroke severity will be controlled for by including the NIHSS4 at baseline as a 
fixed factor in the model. Recruitment site will be included as a random effect. 
3.6.2.3 Handling of Missing Data: 
Missing data for secondary analyses will be handled as per section 3.5.3.  
 
3.7 Other Secondary Outcomes: Quality of Life 
It is hypothesised that: 
Very early aphasia therapy (UC-Plus and VERSE) will result in better quality of life at 12 and 26 
weeks post stroke than UC control. 
 
3.7.1 Outcome measure for Quality of Life 
Quality of life will be assessed using the Stroke and Aphasia Quality of Life Scale (SAQoL).17 
 
3.7.2 Statistical Hypotheses for Quality of Life 
The specified quality of life hypotheses involve the assessment of the following statistical hypotheses: 
1. Very early daily aphasia therapy (UC-Plus or VERSE) will result in higher quality of life 
than Usual Care alone at 12 weeks post stroke.  
2. VERSE aphasia therapy will result in higher quality of life than Usual Care alone at 12 
weeks post stroke. 
3. UC-Plus will result in higher quality of life than Usual Care alone at 12 weeks post stroke. 
4. VERSE aphasia therapy will result in higher quality of life that UC – Plus at 12 weeks 
post stroke. 
5. Very early intensive aphasia therapy (UC-Plus or VERSE) will result in greater 
improvements in communication ability at 26 weeks post stroke. 
6. VERSE aphasia therapy will result in higher quality of life than Usual Care alone at 26 
weeks post stroke. 
7. UC- Plus will result in higher quality of life than Usual Care alone at 26 weeks post stroke. 
8. VERSE aphasia therapy will result in higher quality of life that UC – Plus at 26 weeks 
post stroke. 
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3.7.1 Analysis Method: 
Separate linear mixed effects regression model will be used to assess quality of life as measured by 
the SAQoL17 at 12 weeks post stroke and at 26 weeks post stroke. Each model will compare the 
effects of: 
1. VERSE therapy to usual care alone  
2. UC- Plus therapy to usual care alone  
The model will adjust for baseline aphasia severity by including the WAB-R (AQ)2 score at baseline 
as a covariate. Baseline stroke severity will be controlled for by including the NIHSS4 at baseline as 
a fixed factor in the model. Recruitment site will be included as a random effect. The treatment effects 
will be reported as difference in SAQoL17 (between VERSE and UC and between UC- Plus and UC); 
the corresponding 95% confidence intervals will be reported. 
3.7.1.1 Handling of Missing Data: 
Handling of missing data will be similar to the detail in section 3.5.3.  
 
3.8 Other Secondary Outcomes: Cost Effectiveness 
It is hypothesised that: 
Very early intensive aphasia therapy (UC-Plus and VERSE) will be more cost-effective than Usual 
Care at 26 weeks post stroke. 
 
3.8.1 Analysis Method: 
Details of the cost effectiveness analyses will be published separately and are not included here. 
Results from the effectiveness analyses will be the same for describing the effectiveness component 
of the incremental cost effectiveness calculation. 
 
3.9 Secondary Outcomes: Safety Important Medical Events (IME) Adverse Events (AE) and 
Serious Adverse Events (SAE) 
Important Medical Events (IMEs), Adverse Events (AEs) and Serious Adverse Events (SAEs) are 
defined in the main trial protocol. These are expected to be rare occurrences. Aphasia therapy is not 
expected to have an effect on these events. Therefore, no formal hypotheses have been stated about 
these outcomes. All IMEs, AEs and SAEs will be reported by therapy group. 
As rare events, counts of IMEs, AEs and SAEs are expected to have a Poisson or negative binomial 
distribution. The distributions of these events will be modelled and appropriate generalised linear 
mixed models will be developed to assess differences between groups if the data suggests that there 
is a between-group difference of greater than 3 standard deviations in any of these event types. 
 
3.10 Sensitivity Analyses 
Sensitivity analysis for the primary outcome will be conducted under various assumptions about the 
missing data. The main analysis is planned under an assumption of missing at random; therefore, the 
sensitivity of the results to plausible departures from MAR will be explored as a part of an intention-
to-treat analysis strategy.25-27 
The 2010 National Research Council Panel on the Handling of Missing Data in Clinical Trials27 
outlined two frameworks for modelling missing data:  selection models and pattern-mixture models. 
The selection model framework models the probability of nonresponse (data being missing) rather 
than the distribution of the outcomes. In contrast, the pattern-mixture model framework models the 
distribution of the outcomes, under the assumption that the distribution of outcomes is different for 
responders and non-responders. The pattern-mixture model framework admits a transparent and 
easily-interpretable method for conducting a sensitivity analysis which involves adding a parameter 
 Page 18 of 29 
VERSION 1.1    
DATE:  28 March 2018 
   
 
 
(delta) to the mean response. The parameter, delta, measures the degree of departure from missing at 
random. In the VERSE trial, we propose using a pattern-mixture model to conduct a sensitivity 
analysis that assesses sensitivity of the results to plausible departures from the MAR assumption. If 
the inference about the treatment effects can be overturned by plausible values of the delta parameter, 
then the results of the trial will be considered equivocal. 
We note that the gain in transparency and interpretability of conducting sensitivity analyses for 
pattern-mixture models may be offset by the computational complexity in averaging across large 
numbers of patterns in models with a large number of repeated measures. We do not anticipate facing 
this issue in the VERSE trial since outcomes are measured at only two timepoints after baseline (at 
primary endpoint and at follow up). However, if for any reason, we are unable to conduct a sensitivity 
analysis under the pattern-mixture model framework, the sensitivity analysis will be conducted under 
an appropriate selection model framework. 
 
 
3.11 Tables and Figures for the Main Paper 
The proposed tables and figures for the main results are presented in Appendix 1. Table 1 will report 
the main baseline demographic and stroke characteristics by participant group. Table 2 will report 
baseline communication, cognition and swallowing characteristics. Table 3 will report key summary 
data about the timing, frequency of therapy and amount of therapy provided in each group, length of 
hospital stay and discharge destination. Tables 4 and 5 will report the primary and main secondary 
outcomes at 12 and 26 weeks post stroke and Table 6 will report deaths and Serious Adverse Events. 
Figure 1 will be the CONSORT22 diagram. Figure 2 will be a bar chart of each grade on the mRS5 in 
each treatment group at 12 and 26 weeks post stroke. Figure 3 will be a forest plot of the treatment 
effect on the primary outcome among different subgroups at 12 and 26 weeks post stroke.  
 
3.12 Approval 
The final version of this statistical analysis plan was approved by the Executive Committee on 20th 
December 2017. 
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Appendix 1 
 
Table 1: Baseline Participant and Stroke Characteristics 
 
 UC UC+ VERSE All 
 n (%) n (%) n (%) n (%) 
Recruitment Region     
Australia     
New Zealand     
Patient Details     
Age Median (IQR)     
<65     
65-80     
>80     
Gender     
Male     
Female     
Pre-morbid History (Living arrangements prior 
to stroke) 
    
Home alone     
Home with other     
Supported accommodation     
Unknown     
Stroke Risk Factors     
HTN     
IHD     
AF     
Hypercholesterolaemia     
Diabetes     
Smoking     
Baseline NIHSS, Mean (SD)     
Baseline mRS (binary)     
Low (0-2)     
High (3-6)     
Oxfordshire Stroke Classification     
TACS     
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PACS     
POCS     
LACS     
Haemorrhage     
Time to Randomisation (days), Median (IQR)*     
 
*n.b.  time calculated from stroke onset to randomisation
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Table 2: Baseline communication, swallowing and cognition characteristics 
 
 UC UC+ VERSE All 
 n (%) n (%) n (%) n (%) 
Frenchay Aphasia Screening Test Median (IQR)     
Baseline Western Aphasia Battery - Revised AQ Mean 
(SD) 
    
Ceiling (93.7 - 100)  
Mild  (93.6 - 62.6) 
Moderate (62.5 –  31.3) 
    
Severe (0 – 31.2)     
Baseline Discourse Measures     
No. of Words, Mean (SD)     
No. CIUs, Mean (SD)     
% CIUs , Mean (SD)     
Boston Naming Test, Mean (SD)     
AuSTOMS     
Dysarthria     
No impairment     
Mild impairment     
Moderate impairment     
Moderate/severe impairment     
Profound impairment     
Apraxia of Speech (AoS)     
No impairment     
Mild impairment     
Moderate impairment     
Moderate/severe impairment     
Profound impairment     
Clock Drawing/Cog Test, Median (IQR) 
RBHOMS 
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Table 3: Hospital Stay and intervention Characteristics  
  UC UC+ VERSE All 
Length of Inpatient Hospital Stay* 
Median (IQR) 
     
Time to first therapy,* Median 
(IQR) 
     
Received Therapy as Inpatient n (%)      
Met Intervention Compliance n (%)      
Intervention number of Therapy 
Sessions, Median (IQR)+ 
Usual Ward Care     
Intense Therapy     
Frequency: Sessions per week, 
Median (IQR) 
Usual Ward Care     
Intense Therapy     
Length of Session,# Mean (SD) Usual Ward Care     
Intense Therapy     
Intervention period+ Total Therapy 
Amount ^ Mean (SD) 
Usual Ward Care 
Intense Therapy 
    
Week 12 Total Therapy Amount, ^ 
Mean (SD) 
Usual Ward Care     
Intense Therapy     
Week 26 Total Therapy Amount, ^ 
Mean (SD) 
Usual Ward Care     
Intense Therapy     
n.b. * calculated in days +Intervention period defined as 35 days post randomisation; 
#calculated in minutes; ^calculated in hours 
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Table 4:  
Outcomes at 12 weeks 
 
 UC UC+ VERSE ALL 
Primary Outcome Measure      
Western Aphasia Battery – Revised AQ, Mean (SD)     
 % Maximal Potential Recovery (MPR)     
Secondary Outcomes     
Discourse Measures     
No. of Words, Mean (SD)     
No. CIUs, Mean (SD)     
% CIUs, Mean (SD)     
Boston Naming Test, Mean (SD)     
Stroke and Aphasia Quality of Life Scale, Mean (SD)     
Aphasia Depression Rating Scale, Mean (SD)     
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Table 5: Outcomes at 26 weeks 
 
 
 UC UC+ VERSE ALL 
Primary Outcome Measure      
Western Aphasia Battery – Revised AQ, Mean (SD)     
 % maximal potential recovery (%MPR)     
Secondary Outcomes     
Discourse Measures     
No. of Words, Mean (SD)     
No. CIUs, Mean (SD)     
% CIUs, Mean (SD)     
Boston Naming Test, Mean (SD)     
Stroke and Aphasia Quality of Life Scale, Mean (SD)     
Aphasia Depression Rating Scale, Mean (SD)     
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Table 6: Adverse Events and Serious Adverse Events 
 
 
 UC UC+ VERSE All 
 n n n n 
No. of Adverse Events (AEs)     
Deaths     
Depression     
Important medical events     
Neurological Complications     
0     
1     
2     
> 2     
No. of Serious Adverse Events (SAEs)     
0     
1     
2     
> 2     
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Figure 1. CONSORT Flow Diagram 
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Figure 2. Figure 2. WAB-R (AQ) baseline, 12 and 26 week outcomes 
 
Figure 3. Forest plot of treatment effect on primary outcome among different subgroups. 
 
